Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Is Acadia Pharmaceuticals Inc. stock overvalued or undervalued in 2026?
Acadia Pharmaceuticals Inc. (ACAD) trades at 9.2× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Acadia Pharmaceuticals Inc.
Market cap $4B · 52 weeks $19 – $31 (33 % below the high) · P/E 9.2× · 2027 est. P/E 21.8× · Dividend none · Next earnings November 4, 2026 · expected EPS $0.20 · Closing price, Nov 2 · accounts published Aug 4.
- Valuation: P/Sales 1.6× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- Market cap / Cash 4.2×, fails.
- R&D / Market cap 9.5 %, borderline.
- Annual cash burn $0.65, passes.
- Total Debt 0.1×, passes.
Against its peers (reference peers) — Acadia Pharmaceuticals Inc.: P/E 9.2×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B. Arcutis Biotherapeutics, Inc. (P/E 150×; EV/EBITDA 94.7×; ROIC 9.9 %; $3.9B), Telix Pharmaceuticals Limited (P/E 96.1×; EV/EBITDA 114×; ROIC -0.6 %; $3.1B), Nurix Therapeutics, Inc. (P/E 11.1×; EV/EBITDA 7.0×; ROIC 25.9 %; $2.8B).
Profitability
| Return on Equity | 32.39% |
| Return on Invested Capital | 6.19% |
| Return on Assets | 21.83% |
| Gross Margin | 91.13% |
| Operating Margin | 7.59% |
| Net Margin | 33.42% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 3.39 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 7.94 |
Price Performance
| 1 month | +3.21% |
| 3 months | -24.16% |
| Year-to-date | -22.91% |
| 1 year | -9.30% |
| 3 years | -14.46% |
| 5 years | +1.08% |
| 10 years | -5.07% |
Related companies: AXSM · PRAX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks